Is Abzena the new force in building better biopharmaceuticals?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Is Abzena the new force in building better biopharmaceuticals?
Released on: September 05, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Biopharmaceuticals are an increasingly important class of medicines with over 400 products estimated to be in clinical development and the market expected to increase from US$199.
  • Summary
  • Transcript
  • Participants
  • Company
Biopharmaceuticals are an increasingly important class of medicines with over 400 products estimated to be in clinical development and the market expected to increase from US$199.7 billion in 2013 to US$497.9 billion by 2020. John Burt, CEO, tells Adrian Dawkes how Abzena is providing key services to pharmaceutical companies which will enable them to produce the next generation of protein therapeutics. Combining the proven technologies established brands of its wholly-owned subsidiaries, PolyTherics and Antitope, Abzena offers a suite of key capabilities services and technologies including Immunogenicity assessment, antibody drug conjugation, antibody and protein engineering, optimisation of pharmacokinetics and cell line development.
Biopharmaceuticals are an increasingly important class of medicines with over 400 products estimated to be in clinical development and the market expected to increase from US$199.7 billion in 2013 to US$497.9 billion by 2020. John Burt, CEO, tells Adrian Dawkes how Abzena is providing key services to pharmaceutical companies which will enable them to produce the next generation of protein therapeutics. Combining the proven technologies of its wholly-owned subsidiaries, PolyTherics and Antitope, Abzena offers a suite of key capabilities including Immunogenicity assessment, antibody drug conjugation, antibody and protein engineering, optimisation of pharmacokinetics and cell line development.
John Burt
Abzena
Abzena
Biopharmaceuticals are an increasingly important class of medicines with over 400 products estimated to be in clinical development and the market expected to increase from US$199.7 billion in 2013 to US$497.9 billion by 2020. Antibody-based products and therapeutic proteins are the two largest and fastest growing segments of this market. Abzena provides a suite of complementary services and technologies to R&D organisations to improve the chances of successful development of therapeutic proteins and antibodies, and it is therefore poised to capitalise on the growth of the biopharmaceutical market. The Group has significant know-how, supported by a broad patent estate, to enable it to create better biopharmaceuticals for its customers. Abzena operates a balanced business model with growing revenues from its service business and the potential for significant future growth through royalty bearing licences for the application of its technologies to biopharmaceutical products. The Group’s technologies and services are provided through its wholly-owned subsidiaries, PolyTherics and Antitope. PolyTherics and Antitope have been developing and offering their technologies and services for over 10 years and their scientists have provided expertise to a wide range of companies, including most of the top 20 biopharmaceutical companies, many large and small public and private biotech, and academic groups, across the world.